HYUNDAI BIOLAND Co.Ltd (052260) fair value: what the stock is really worth
We calculate from audited financials what HYUNDAI BIOLAND Co.Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch HYUNDAI BIOLAND Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 3,225 KRW – 11,341 KRW · the 3,980 KRW price screens above the 2,740 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients.
Show more
HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients. The company was formerly known as SKbioland Co., Ltd. and changed its name to HYUNDAI BIOLAND Co.,Ltd in October 2020. HYUNDAI BIOLAND Co.,Ltd was incorporated in 1995 and is based in Cheongju, South Korea.
Stock analysis
HYUNDAI BIOLAND Co.Ltd (052260) currently trades at 3,980 KRW, while our model-based Fair Value estimate is 2,740 KRW, implying the stock looks roughly 45.2% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 7,199 KRW per share, and 13 of the 24 models we run sit above the 3,980 KRW price.
Bear case: the Economic Profit group reads lowest at 2,750 KRW, and 11 of the 24 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Consumer Non-Cyclicals sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
HYUNDAI BIOLAND Co.Ltd reported revenue of 131B KRW in FY2025 versus 103B KRW in FY2021, a compound +6.1%/yr. Reported net income was 253M KRW in FY2025.
Key figures
Market cap 119B KRW (≈ $83.6M) · P/S ratio 1.01 · Dividend yield 1.7% · Net margin 0.2% · Return on equity 1,004% · Return on assets (EBIT) 3.8% · Operating margin 9.9% · Revenue (TTM) 103B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).
What moves the price
The share trades about 25% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −16% fair-value upside, at −31%, 052260 screens richer than that median.
Fair Value models
Bear 2,740 KRWFair Value 2,740 KRWBull 2,740 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−12.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.6%
Dividend (yield on the price)1.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−59% vs −37%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−19% → 10%
⚠ Revenue per share shrinking 7.2%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.4%
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Personal & Household Products & Services” was too small, so the broader sector is used.)Consumer Staples · 1788 stocks
Beats the sector median on 4/7 measures
A mixed picture versus its sector peers.
Valuation
Quality Score60 · Above median
Profitability
Return on assets3% · Above median
Net margin (TTM)−9% · Bottom 25%
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth−6% · Bottom 25%
Dividend yield (TTM)1.7% · Below median
Valuation Multiplesvs Consumer Staples median · lower = cheaper
P/FCF0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 29
FUTURE (revenue growth)0· sector 15
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)34· sector 55
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HYUNDAI BIOLAND Co.Ltd (052260) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 2,740 KRW versus a price of 3,980 KRW, about −31% upside (overvalued).
What is the fair value of 052260?
Our model-based fair value for HYUNDAI BIOLAND Co.Ltd is 2,740 KRW (as of Sep 13, 2026), built from audited fundamentals. The current price: 3,980 KRW.
What is the quality score of 052260?
HYUNDAI BIOLAND Co.Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HYUNDAI BIOLAND Co.Ltd (052260)?
Our model-based price target is the fair value of 2,740 KRW (as of Sep 13, 2026) from 24 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the HYUNDAI BIOLAND Co.Ltd stock forecast for 2026?
Our models put fair value at 2,740 KRW, about −31% upside versus a price of 3,980 KRW (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of HYUNDAI BIOLAND Co.Ltd (052260)?
HYUNDAI BIOLAND Co.Ltd reported trailing-twelve-month revenue of about 103B KRW (latest available figure, as of Sep 13, 2026).
Does HYUNDAI BIOLAND Co.Ltd pay a dividend?
HYUNDAI BIOLAND Co.Ltd currently shows a dividend yield of about 1.72% relative to its recent price (as of Sep 13, 2026).
What growth is priced into HYUNDAI BIOLAND Co.Ltd (052260)?
For today's price to be fair in a discounted-cash-flow model, HYUNDAI BIOLAND Co.Ltd would have to grow free cash flow by -5.4 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.0 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 052260 use?
Our models discount HYUNDAI BIOLAND Co.Ltd at 12.4 %: a base by market capitalisation (micro), damped by beta 0.77, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HYUNDAI BIOLAND Co.Ltd that is -5.4 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has HYUNDAI BIOLAND Co.Ltd (052260) delivered so far?
Over the past 5 years revenue at HYUNDAI BIOLAND Co.Ltd grew +8.0 % a year. The price currently implies -5.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HYUNDAI BIOLAND Co.Ltd (052260) growing?
The median revenue growth in the sector is +3.0 % a year. That is the yardstick for the growth priced into HYUNDAI BIOLAND Co.Ltd (-5.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HYUNDAI BIOLAND Co.Ltd (052260)?
The free-cash-flow yield on the price is 12.90 %: that much free cash flow HYUNDAI BIOLAND Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HYUNDAI BIOLAND Co.Ltd (052260)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HYUNDAI BIOLAND Co.Ltd it is 2,740 KRW per share (as of Sep 13, 2026), against a price of 3,980 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is HYUNDAI BIOLAND Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 052260 trades above its calculated fair value: price 3,980 KRW, fair value 2,740 KRW, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 052260?
No. The price is what the market pays today (3,980 KRW); the fair value is what the company's own numbers justify (2,740 KRW). For HYUNDAI BIOLAND Co.Ltd the two are 1,240 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HYUNDAI BIOLAND Co.Ltd worth?
The market values HYUNDAI BIOLAND Co.Ltd at about 119B KRW (market capitalisation, as of Sep 13, 2026). Per share that is 3,980 KRW; our models calculate a fair value of 2,740 KRW per share.
How far is 052260 from its 52-week high?
HYUNDAI BIOLAND Co.Ltd trades at 3,980 KRW, about 25% below its 52-week high of 5,330 KRW and 13% above the low of 3,510 KRW (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 2,740 KRW is for.
Which stocks are comparable to HYUNDAI BIOLAND Co.Ltd?
From the same area (Consumer Non-Cyclicals) we also value NeoPharm CO., LTD., Csa Cosmic Co, AUX, FB, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HYUNDAI BIOLAND Co.Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price 3,980 KRW, calculated fair value 2,740 KRW (−31%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 052260 calculated?
We run HYUNDAI BIOLAND Co.Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,740 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. HYUNDAI BIOLAND Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with HYUNDAI BIOLAND Co.Ltd right now?
The price sits above even our optimistic bull case (2,740 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of HYUNDAI BIOLAND Co.Ltd
How large is the market capitalisation of HYUNDAI BIOLAND Co.Ltd (052260)?
The market capitalisation of HYUNDAI BIOLAND Co.Ltd is 119B KRW (≈ $83.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HYUNDAI BIOLAND Co.Ltd (052260)?
The price-to-sales ratio of HYUNDAI BIOLAND Co.Ltd is 1.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of HYUNDAI BIOLAND Co.Ltd (052260)?
The dividend yield of HYUNDAI BIOLAND Co.Ltd is 1.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HYUNDAI BIOLAND Co.Ltd (052260)?
The net margin of HYUNDAI BIOLAND Co.Ltd is 0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HYUNDAI BIOLAND Co.Ltd (052260)?
The return on equity (ROE) of HYUNDAI BIOLAND Co.Ltd is 1,004% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HYUNDAI BIOLAND Co.Ltd (052260)?
On an EBIT basis the return on assets of HYUNDAI BIOLAND Co.Ltd is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HYUNDAI BIOLAND Co.Ltd (052260)?
The operating margin of HYUNDAI BIOLAND Co.Ltd is 9.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HYUNDAI BIOLAND Co.Ltd (052260)?
Revenue at HYUNDAI BIOLAND Co.Ltd is growing −6.0% versus a year earlier (3y avg +9.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HYUNDAI BIOLAND Co.Ltd (052260)?
Earnings per share at HYUNDAI BIOLAND Co.Ltd are growing +37.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does HYUNDAI BIOLAND Co.Ltd (052260) carry?
The net debt of HYUNDAI BIOLAND Co.Ltd is 13.7B KRW (fiscal year 2024, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch HYUNDAI BIOLAND Co.Ltd in the live analysis
One click puts HYUNDAI BIOLAND Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
